MAP4343

A metabolically stable pregnenolone analog that works through microtubule dynamics (MAP2) rather than GABA-A or NMDA receptors, positioning it as a first-in-class cytoskeletal antidepressant candidate.

Human safety data for MAP4343 are limited because it remains an investigational compound that has not received regulatory approval, and no long-term human tolerability record exists in the public literature. Preclinical work across rats, tree shrews and mice using subcutaneous dosing did not report overt toxicity, and its design specifically avoids conversion into hormonally active steroids, which theoretically limits classical endocrine side effects.

In a mouse model of alcohol dependence, chronic MAP4343 counteracted the drop in plasma corticosterone caused by alcohol withdrawal but in some withdrawal contexts reduced open-arm exploration on the elevated plus maze, a readout that can indicate an anxiogenic-like shift; this context dependence warrants caution. Because pharmacokinetic, drug-interaction and reproductive-safety profiles in humans are not established, MAP4343 should be regarded as experimental and not self-administered.

MAP4343 emerged from the neurosteroid research program of Étienne-Émile Baulieu, the endocrinologist who earlier co-developed the antiprogestin mifepristone (RU-486) and who coined the term "neurosteroid." Working with colleagues including Paul Robel, Esther Fellous and Massimiliano Bianchi, the group filed patents from the early 2000s (for example WO2004067010 and later filings) covering 3-methoxy-pregnenolone for neurodegenerative and depressive disorders, and founded the biotechnology company Mapreg to develop it. A pivotal 2006 study in the Proceedings of the National Academy of Sciences identified MAP2 as a neurosteroid receptor for pregnenolone and its methoxy analog, providing the mechanistic rationale.

In 2012 Bianchi and Baulieu published in the same journal that MAP4343 produced rapid, persistent antidepressant-like effects in rodent models, faster and more durable than fluoxetine. Subsequent studies extended its testing to chronic psychosocial stress in tree shrews, experimental spinal cord injury, Huntington's disease neuron models via the daf-16/FOXO stress-response pathway, and an alcohol use disorder mouse model. The compound advanced into early clinical development as a candidate for depression and stress-related disorders.

Within neuropsychopharmacology MAP4343 is regarded as a scientifically intriguing, first-in-class candidate because it targets the neuronal cytoskeleton rather than the monoamine or GABAergic systems addressed by existing antidepressants, and it features prominently in review articles surveying investigational and novel-mechanism antidepressants. Its association with Baulieu lends it credibility, and preclinical results have been consistent across several independent stress and addiction models. At the same time its reputation remains that of a niche, early-stage investigational agent; robust published human efficacy data are sparse, and it is largely unknown outside specialist neurosteroid and cytoskeletal-plasticity research circles. It is not available as a supplement and has no established place in clinical practice.